Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions.
Biovitrum focuses on the development and production of biopharmaceuticals within our prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care, and fat malabsorption.
In 2009 Biovitrum had net sales of SEK 1.3 billion and 380 employees at the end of the year.
Biovitrum’s mission is to develop and sell specialist pharmaceuticals that improve people’s lives. The business goal is to be a pharmaceutical company with long-term profitability. Biovitrum develops its portfolio of specialist care projects internally or with partners to be able to generate future revenues.
In 2009 the company generated revenues through:
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Every day, we work actively to find better ways to understand and meet patient needs.
Find out more about our business and financial performance.
Here we present our most recent press releases, news articles, and images.